Evidence | Ovarian cancer: identifying and managing familial and genetic risk | Guidance | NICE

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

Other supporting evidence
Supplement 1: Methods ^{PDF 422 KB} 21 March 2024
Evidence review
A: Information and support ^{PDF 3.18 MB} 21 March 2024
B: Support interventions ^{PDF 1.7 MB} 21 March 2024
C: Configuration of services ^{PDF 1.24 MB} 21 March 2024
D: Optimal methods of assessing the probability of having a pathogenic variant ^{PDF 8.83 MB} 21 March 2024
E: Optimal methods of assessing the absolute risk of having a pathogenic variant ^{PDF 849 KB} 21 March 2024
F: Carrier probability – any person ^{PDF 1.71 MB} 21 March 2024
G: Carrier probability – family history of a syndrome ^{PDF 633 KB} 21 March 2024
H: Populations with high prevalence ^{PDF 2.43 MB} 21 March 2024
I: Carrier probability – people with ovarian cancer ^{PDF 905 KB} 21 March 2024
J: Which genes to include in gene panel testing ^{PDF 1.65 MB} 21 March 2024
K: Benefits and risks of surveillance ^{PDF 1.25 MB} 21 March 2024
L: Methods of surveillance ^{PDF 4.1 MB} 21 March 2024
M: Preventive medicines ^{PDF 1.36 MB} 21 March 2024
N: Risk-reducing surgery ^{PDF 1.88 MB} 21 March 2024
O: Pathology protocol ^{PDF 4.15 MB} 21 March 2024
P: Hormone replacement therapy after risk-reducing surgery ^{PDF 1.83 MB} 21 March 2024
Evidence reviews – March 2024
Economic analysis
Supplement 2: Economic literature ^{PDF 734 KB} 21 March 2024